Inflection Biosciences Ltd is an early stage, drug development company with a focus on discovering and developing innovative small molecule therapeutics addressing major unmet needs in cancer.

Biotechnology

Inflection Biosciences

Inflection Biosciences' headquarters in Blackrock, Ireland

Darren Cunningham

Michael O'Neill

Gerry McGettigan

Gemma Carroll

Tess Barker

John Lynch

Josep Tabernero

Martin Buckland

Conor Mallaghan

Funda Meric Bernstam

Martin Dreyling

Micheall O'Neill

Arthur Pratt

Andrew Leishman

Patrick Walsh

The Regulatory Affairs team at Inflection Biosciences plays a critical role in ensuring that the company’s drug development processes comply with regulatory standards and guidelines. They are responsible for preparing and submitting documentation to regulatory agencies, liaising with authorities, and providing strategic advice on regulatory pathways to expedite the approval of innovative cancer therapeutics. Their expertise supports the overall goal of advancing drug candidates from research through to clinical trials and market entry.

Regulatory Affairs

The Scientific Research and Development team at Inflection Biosciences is dedicated to advancing the discovery and development of novel small molecule therapeutics for cancer treatment. This multidisciplinary team, comprising experts in preclinical formulation development, translational oncology, and process chemistry, collaborates to optimize drug formulations, translate scientific insights into clinical applications, and ensure efficient manufacturing processes, all aimed at addressing critical unmet needs in oncology.

Scientific Research and Development

��

Inflection Biosciences

Org chart

Board & advisors

Teams

Regulatory Affairs

Scientific Research and Development

Offices

��������

Inflection Biosciences

Org chart

Board & advisors

Teams

Regulatory Affairs

Scientific Research and Development

Offices

Related companies

��